Immutep Limited (Nasdaq: IMMP) has received positive feedback from the US Food and Drug Administration (FDA) for its late-stage clinical development plans for Eftilagimod Alpha ("efti") in the treatment of 1st line non-small cell lung cancer. In addition, the company announced a successful initial overall survival rate in the Phase II TACTI-002 trial for efti in combination with MSD's (Merck & Co., Inc.) KEYTRUDA.

$IMMP's pre-market trading reflects the positive developments, with the stock currently trading at $1.89, up $0.30 or 18.96%.

In other news, Lightning eMotors, Inc. (NYSE: ZEV) reported a Q1 2023 loss of $4.89 per share, which missed the consensus estimate of a loss of $4.15 per share. Despite the disappointing earnings report, the company announced a $50 million pre-paid advance agreement with an investment fund managed by Yorkville Advisors Global L.P.

In pre-market trading, $ZEV is valued at $4.21, experiencing a decline of $0.07 or 1.64%.

Lastly, BioNTech SE (Nasdaq: BNTX) received an upgrade from Redburn, with the rating being raised from Neutral to Buy and the price target being increased to $170 from $165.

In the pre-market session, shares of $BNTX are trading at $106.97, reflecting an increase of $1.37 or 1.30%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)